B. Riley Securities Initiates Coverage On Arcturus Therapeutics with Buy Rating, Announces Price Target of $22

B. Riley Securities has initiated coverage on Arcturus Therapeutics (NASDAQ: ARCT) with a Buy rating. The analyst, Mayank Mamtani, has set a price target of $22 for the company's stock.